AUG 10, 2016 10:23 AM PDT

Hopkins Doctors Challenge Routine Testing for Breast Cancer

WRITTEN BY: Xuan Pham
When it comes to some cancer types, more testing may not always pay off. It may, in fact, waste millions of dollars that could go towards other healthcare burdens. That’s what Johns Hopkins doctors report, after finding that for a common type of noninvasive breast cancer, routine testing at the onset of diagnosis may be redundant and highly wasteful. How wasteful? The scientists estimated at least $35 million could be saved annually if this initial testing was not made so routine.

Every year, an estimated 60,000 patients in the US are diagnosed with a noninvasive breast cancer type known as ductal carcinoma in situ (DCIS). This condition is marked by presence of cancer cells in the milk ducts or lobules, which have not spread to anywhere else.

According to Hopkins researchers, it’s become almost a reflex for doctors nationwide to order core needle biopsies for hormone receptor testing following a DCIS finding. The routine procedure determines whether the cancer is noninvasive or invasive, and tests for the presence of estrogen and progesterone receptors.

But, regardless of the outcome of the biopsy, doctors end up making the same recommendation: lumpectomy or mastectomy to remove the cancerous tissues. This is the first line of argument against the needle biopsy.

Furthermore, the first round of testing shows itself to be essentially redudant later on. Pedram Argani, senior lead of the study said, “Almost 20 percent of the time, the excision reveals that the noninvasive DCIS that the core needle biopsy caught is actually accompanied by invasive breast cancer. So you have to receptor-test the invasive cancer that the core biopsy missed. That means the testing of the core biopsy with DCIS was useless."
 

But perhaps the most compelling argument to drop the initial needle biopsy may be its demonstrated lack of efficacy on patient survival. The premise behind this treatment is to catch hormone receptor-positive DCIS types, for which tamoxifen can be taken to inhibit the receptors and prevent cancer recurrence. However, the effect of this treatment overall is modest at best, while the side effects can be severe.

"Two-thirds of our DCIS study patients did not receive hormone therapy," said Argani, "even after excision confirmed their hormone-receptor positive DCIS status. So analyzing their needle biopsies or surgical excisions for receptors would have clearly been unnecessary for them."

What it amounts to, in the researchers’ perspective, is an expensive medical bill that’s not necessary. Every early receptor test costs about $140 per patient. "Extrapolating that to the roughly 60,000 U.S. patients diagnosed with DCIS yearly puts the cost at about $8.5 million," added Argani. "The unnecessary cost of automatically testing DCIS in excisions when the information is not used is $26.5 million, which adds up to $35 million dollars per year in the U.S."

So persuasive are the results that the Johns Hopkins Hospital have already abandoned this practice at the start of the year, 8 months before the formal publication of the study. Perhaps other hospitals will also follow suit.

Additional source: Johns Hopkins press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 14, 2019
Drug Discovery & Development
OCT 14, 2019
Anti-cancer Drug Disguises as Fat
According to a study published in the Journal of the American Chemical Society (JACS), a new drug-delivery system disguises as fat in order to outsmart tum...
OCT 14, 2019
Cancer
OCT 14, 2019
New hope for ovarian cancer
Ovarian cancer affects roughly 1 in 78 women and although survival rates are high (over 90%) with early diagnosis, we currently do not have a way to test f...
OCT 14, 2019
Cancer
OCT 14, 2019
Ladies, chicken or steak?
Ladies, trying to choose between chicken or steak? New research published in the International Journal of Cancer might help you decide. According to the st...
OCT 14, 2019
Drug Discovery & Development
OCT 14, 2019
Unprecedented Therapeutic Found Effective for Blood Cancer
According to the findings of a clinical trial, scientists at Mt. Sinai have found a new therapeutic effective for patients with a particular type of b...
OCT 14, 2019
Drug Discovery & Development
OCT 14, 2019
Promising Drug for Prostate Cancer
Using high-throughput screening methods, cancer researchers from the UK have identified some promising drug candidates to test thousands of molecules. Spec...
OCT 14, 2019
Cell & Molecular Biology
OCT 14, 2019
New Type of CAR T-Cell Therapy Headed for Clinical Trials
Scientists have been trying to use the immune system in cancer patients' bodies to fight cancer....
Loading Comments...